Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Canakinumab in CAPS
NCT00685373Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2008
- Primary completion
- Apr 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of canakinumab in familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), neonatal-onset multisystem inflammatory disease (NOMID), sponsored by Novartis. Started May 2008; status: completed.
02
Drugs
canakinumab
03
Conditions
familial cold autoinflammatory syndrome (FCAS)Muckle-Wells syndrome (MWS)neonatal-onset multisystem inflammatory disease (NOMID)
Beyond the preview
Go deeper on NCT00685373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00685373.